(Q37972755)

26 August 2017

title

New targets for antiviral therapy of chronic hepatitis C. (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Ralf Bartenschlager

2

0 references

author name string

Sandra Bühler

series ordinal

1

1 reference

26 August 2017

publication date

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

32 Suppl 1

1 reference

26 August 2017

page(s)

9-16

1 reference

Viral hepatitis and liver cancer: the case of hepatitis C.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Nomenclature and numbering of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus entry: possible targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

RNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus Endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

New insights into structure and replication of the hepatitis C virus and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Assembly of infectious hepatitis C virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Persistent and transient replication of full-length hepatitis C virus genomes in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus resistance to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

New hepatitis C therapies in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Identification of Hepatitis C Virus NS5A Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Changes in autophagic response in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Cyclophilin D is required for mitochondrial removal by autophagy in cardiac cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

microRNA-122 stimulates translation of hepatitis C virus RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

New NS5B polymerase inhibitors for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02701.X

10.1111/J.1478-3231.2011.02701.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference